KH001 for Tooth Sensitivity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called KH001 to determine its effectiveness in reducing tooth sensitivity, also known as dentin hypersensitivity, and to ensure its safety. Participants will be divided into groups to receive either the KH001 treatment or a placebo (a substance with no active drug). The trial seeks individuals with at least two sensitive teeth that are not adjacent. If tooth sensitivity disrupts daily activities like eating or drinking cold foods, this trial might be suitable. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that KH001 is likely to be safe for humans?
Research has shown that potassium-based treatments, like KH001, are generally safe for treating tooth sensitivity. Similar treatments, such as potassium chloride and potassium nitrate, were well-tolerated in past studies. Although specific data on KH001's safety in humans remains limited, its progression to a Phase 2 trial indicates it passed initial safety tests. This suggests earlier studies likely found it safe, but further research is needed to confirm this.12345
Why do researchers think this study treatment might be promising?
Most treatments for tooth sensitivity, like desensitizing toothpaste or fluoride gels, work by blocking nerve signals or strengthening enamel. But KH001 works differently, targeting the root cause of sensitivity by repairing the tiny channels in teeth that lead to nerve endings. Researchers are excited about KH001 because of its potential to provide longer-lasting relief by addressing the underlying issue rather than just masking symptoms. Additionally, its unique mechanism could mean fewer applications and faster results compared to traditional treatments.
What evidence suggests that KH001 might be an effective treatment for tooth sensitivity?
Studies have shown that KH001 can significantly reduce pain in people with sensitive teeth. One study with 31 participants found that using gaseous ozone, a component of KH001, led to a 55% drop in pain immediately after treatment. KH001 provides pain relief by blocking the tiny channels in teeth that cause pain. This method is gaining interest because it offers quick relief from the sharp pain caused by exposed dentin, the sensitive part of a tooth. Overall, the initial research appears promising for those dealing with dentin hypersensitivity.
In this trial, researchers will assign participants to different groups, with some receiving KH001 and others receiving a placebo, to further evaluate its effectiveness.23678Who Is on the Research Team?
Hatice Hasturk
Principal Investigator
ADA Forsyth
Are You a Good Fit for This Trial?
This trial is for individuals experiencing tooth sensitivity due to hypersensitive dentin. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and not have conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive three topical applications of KH001 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- KH001
Trial Overview
The study is testing KH001's effectiveness in providing long-term relief from dentin hypersensitivity compared to a placebo. It's a Phase 2 trial, which means it focuses on efficacy and side effects.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
KH001 and placebo
KH001 and placebo
Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
HysensBio Co., Ltd
Lead Sponsor
The Forsyth Institute
Collaborator
Published Research Related to This Trial
Citations
KH001 for Tooth Sensitivity
Treatment with gaseous ozone significantly reduced pain in hypersensitive teeth by 55% immediately after application, based on a study involving 31 subjects ...
A Study to Evaluate the Efficacy and Safety of KH001 in
The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity.
Dentin Sensitivity
Integrated disease information for Dentin Sensitivity including associated genes, mutations, phenotypes, pathways, drugs, and more - integrated from 78 data ...
First‐In‐Human Study of Safety, Tolerability, Efficacy, and ...
ABSTRACT. Dentin hypersensitivity is characterized by transient, sharp pain resulting from dentin exposure due to enamel or cementum loss.
5.
aging.networkofcare.org
aging.networkofcare.org/sanmateo/CommunityResources/ClinicalTrials?keyword=%22Hypersensitivity%20Dentin%22San Mateo Clinical Trials
The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity. Effectiveness of Bioactiveglass Air ...
Phase 2 Study of KH001 in Long-term Relief from Dentin ...
Study Overview. Brief Summary. The purpose of this study is to evaluate the efficacy and safety of KH001 in subjects with dentin hypersensitivity.
7.
ctv.veeva.com
ctv.veeva.com/study/phase-2-clinical-trial-to-evaluate-the-efficacy-and-safety-of-kh001-in-patients-with-dentin-hypersenA Study to Evaluate the Efficacy and Safety of KH001 in ...
The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity.
Dentine Hypersensitivity (DBCOND0046413)
A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity. KH001. treatment, 2, completed. NCT06276777. The Effect of Using ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.